Our COVID19 phase 2 clinical trial for our lead product, rhu-pGSN, has begun.

Steven Opal, M.D.

Steven Opal is Professor of Medicine (Research Scholar Track) in the Infectious Disease Division at The Warren Alpert Medical School of Brown University. He is Chief, Infectious Disease Division at Memorial Hospital of Rhode Island. Dr. Opal’s interests are in the field of septic shock research, endotoxin, cytokines, molecular signaling pathways, microbial mediators, microbial genetics, and antibiotic resistance. The pathophysiology of septic shock is his primary laboratory interest, including the early events that occur in the host-pathogen interaction with systemic infection. Clinical trial design, implementation and analysis from Phase I to Phase III trials is a primary clinical research focus at the present time. He is the editor of several academic research journals and three textbooks in the field of infectious diseases, endotoxin-mediated diseases and septic shock.


Dr. Opal is a member of several professional societies including the Society of Critical Care Medicine, the International Cytokine Society, the Infectious Diseases Society of America and the International Endotoxin and Innate Immunity Society. He is current chair of the International Sepsis Forum. Opal has published more than 200 peer-reviewed research articles and has edited several academic research journals as well as three textbooks on infectious diseases, endotoxin-mediated diseases and septic shock.


Dr. Opal’s received his undergraduate degree from Cornell University and a medical degree from Albany Medical School. He completed his internship and residency in internal medicine at Fitzsimons Army Medical Center in Denver, Colorado, and was a fellow in infectious diseases at Walter Reed Army Medical Center in Washington, D.C.